Citations (108)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (15)
Neil Daksla, Ashley Wang, Zhaosheng Jin, Abhishek Gupta & Sergio D Bergese. (2023) Oliceridine for the Management of Moderate to Severe Acute Postoperative Pain: A Narrative Review. Drug Design, Development and Therapy 17, pages 875-886.
Read now
Read now
Jingwen Niu, Wenmin Hu, Yuntao Lu & Hui Tang. (2023) Efficacy and safety of oliceridine treatment in patients with postoperative pain: a systematic review and meta-analysis of randomized controlled trials. Expert Review of Clinical Pharmacology 16:6, pages 589-599.
Read now
Read now
Qiu Qiu, Joshua CJ Chew & Michael G Irwin. (2022) Opioid MOP receptor agonists in late-stage development for the treatment of postoperative pain. Expert Opinion on Pharmacotherapy 23:16, pages 1831-1843.
Read now
Read now
Eugene R. Viscusi. (2022) A critical review of oliceridine injection as an IV opioid analgesic for the management of severe acute pain. Expert Review of Neurotherapeutics 22:6, pages 419-426.
Read now
Read now
Ammar A.H. Azzam & David G. Lambert. (2022) Preclinical discovery and development of oliceridine (Olinvyk®) for the treatment of post-operative pain. Expert Opinion on Drug Discovery 17:3, pages 215-223.
Read now
Read now
Jill E. Elwing, Hadi Atassi, Benjamin D. Rogers & Gregory S. Sayuk. (2022) Emerging therapies in the management of Irritable Bowel Syndrome (IBS). Expert Opinion on Emerging Drugs 27:1, pages 55-73.
Read now
Read now
Zhaosheng Jin, Mingxi Zhu, Abhishek Gupta, Christopher Page, Tong J Gan & Sergio D Bergese. (2022) Evaluating oliceridine as a treatment option for moderate to severe acute post-operative pain in adults. Expert Opinion on Pharmacotherapy 23:1, pages 9-17.
Read now
Read now
Hon Sen Tan & Ashraf S Habib. (2021) Oliceridine: A Novel Drug for the Management of Moderate to Severe Acute Pain – A Review of Current Evidence. Journal of Pain Research 14, pages 969-979.
Read now
Read now
Hon Sen Tan & Ashraf S. Habib. (2021) Safety evaluation of oliceridine for the management of postoperative moderate-to-severe acute pain. Expert Opinion on Drug Safety 20:11, pages 1291-1298.
Read now
Read now
Abhishek K Gupta, Shayla Mena, Zhaosheng Jin, Tong J Gan & Sergio Bergese. (2021) Postoperative pain: a review of emerging therapeutic options. Expert Review of Neurotherapeutics 21:10, pages 1085-1100.
Read now
Read now
Apoorva Phadke & Purnima Amin. (2021) A Recent Update on Drug Delivery Systems for Pain Management. Journal of Pain & Palliative Care Pharmacotherapy 35:3, pages 175-214.
Read now
Read now
Sergio D Bergese, Marek Brzezinski, Gregory B Hammer, Timothy L Beard, Peter H Pan, Sharon E Mace, Richard D Berkowitz, Kristina Cochrane, Linda Wase, Harold S Minkowitz & Ashraf S Habib. (2019) ATHENA: A Phase 3, Open-Label Study Of The Safety And Effectiveness Of Oliceridine (TRV130), A G-Protein Selective Agonist At The µ-Opioid Receptor, In Patients With Moderate To Severe Acute Pain Requiring Parenteral Opioid Therapy. Journal of Pain Research 12, pages 3113-3126.
Read now
Read now
Eugene R Viscusi, Franck Skobieranda, David G Soergel, Emily Cook, David A Burt & Neil Singla. (2019) APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the µ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy. Journal of Pain Research 12, pages 927-943.
Read now
Read now
Gary M. Oderda, Anthony J. Senagore, Kellie Morland, Sheikh Usman Iqbal, Marla Kugel, Sizhu Liu & Ashraf S. Habib. (2019) Opioid-related respiratory and gastrointestinal adverse events in patients with acute postoperative pain: prevalence, predictors, and burden. Journal of Pain & Palliative Care Pharmacotherapy 33:3-4, pages 82-97.
Read now
Read now
Aliza T. Ehrlich, Brigitte L. Kieffer & Emmanuel Darcq. (2019) Current strategies toward safer mu opioid receptor drugs for pain management. Expert Opinion on Therapeutic Targets 23:4, pages 315-326.
Read now
Read now
Articles from other publishers (93)
David M Hill & Erik DeBoer. (2023) State and Future Science of Opioids and Potential of Biased-ligand Technology in the Management of Acute Pain After Burn Injury. Journal of Burn Care & Research 44:3, pages 524-534.
Crossref
Crossref
Alina C Beaton, Daneshvari Solanki, Hernan Salazar, Steve Folkerth, Neil Singla, Harold S Minkowitz, David Leiman, Ben Vaughn, Nina Skuban & Gwendolyn Niebler. (2023) A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a bupivacaine hydrochloride implant in patients undergoing abdominoplasty. Regional Anesthesia & Pain Medicine, pages rapm-2022-104110.
Crossref
Crossref
Neil Singla & Timothy Rogier. (2023) Abdominoplasty as an acute postoperative pain model: insights from 8 years of clinical trials. Pain 164:2, pages 258-270.
Crossref
Crossref
Jae Min Lee, Yehyun Park, Jin Myung Park, Hong Jun Park, Jun Yong Bae, Seung Young Seo, Jee Hyun Lee, Hyung Ku Chon, Jun-Won Chung, Hyun Ho Choi, Jun Kyu Lee & Byung-Wook Kim. (2022) New sedatives and analgesic drugs for gastrointestinal endoscopic procedures. Clinical Endoscopy 55:5, pages 581-587.
Crossref
Crossref
Lisa R. Gerak, David R. Maguire, Gerta Cami-Kobeci, Keith M. Olson, John R. Traynor, Stephen M. Husbands, Charles P. France, Lisette Acevedo, Barbara Belli & Peter Flynn. (2022) OREX-1038: a potential new treatment for pain with low abuse liability and limited adverse effects. Behavioural Pharmacology 33:6, pages 377-394.
Crossref
Crossref
Sarah Khorsand, Kunal Karamchandani & Girish P. Joshi. (2022) Sedation-analgesia techniques for nonoperating room anesthesia: an update. Current Opinion in Anaesthesiology 35:4, pages 450-456.
Crossref
Crossref
Andrew B. Kleist, Shawn Jenjak, Andrija Sente, Lauren J. Laskowski, Martyna Szpakowska, Maggie M. CalkinsEmilie I. AndersonLisa M. McNallyRaimond Heukers, Vladimir Bobkov, Francis C. Peterson, Monica A. Thomas, Andy Chevigné, Martine J. SmitJohn D. McCorvy, M. Madan Babu & Brian F. Volkman. (2022) Conformational selection guides β-arrestin recruitment at a biased G protein–coupled receptor. Science 377:6602, pages 222-228.
Crossref
Crossref
Brian M. Fung, Deanna J. Leon, Lauren N. Beck & James H. Tabibian. (2021) Pre-procedural Preparation and Sedation for Gastrointestinal Endoscopy in Patients with Advanced Liver Disease. Digestive Diseases and Sciences 67:7, pages 2739-2753.
Crossref
Crossref
Andrea Bedini, Elisabetta Cuna, Monica Baiula & Santi Spampinato. (2022) Quantitative Systems Pharmacology and Biased Agonism at Opioid Receptors: A Potential Avenue for Improved Analgesics. International Journal of Molecular Sciences 23:9, pages 5114.
Crossref
Crossref
Christie B. Palmer, Max Meyrath, Meritxell Canals, Evi Kostenis, Andy Chevigné & Martyna Szpakowska. (2022) Atypical opioid receptors: unconventional biology and therapeutic opportunities. Pharmacology & Therapeutics 233, pages 108014.
Crossref
Crossref
Pablo Castroman, Ovelio Quiroga, Victor Mayoral Rojals, Maria Gómez, Eleni Moka, Joseph Pergolizzi Jr & Giustino Varrassi. (2022) Reimagining How We Treat Acute Pain: A Narrative Review. Cureus.
Crossref
Crossref
Nestor Nivardo Jiménez-Vargas, Yang Yu, Dane D Jensen, Diana Daeun Bok, Matthew Wisdom, Rocco Latorre, Cintya Lopez, Josue O Jaramillo-Polanco, Claudius Degro, Mabel Guzman-Rodriguez, Quentin Tsang, Zachary Snow, Brian L Schmidt, David E Reed, Alan Edward Lomax, Kara Gross Margolis, Christoph Stein, Nigel W Bunnett & Stephen J Vanner. (2022) Agonist that activates the µ-opioid receptor in acidified microenvironments inhibits colitis pain without side effects. Gut 71:4, pages 695-704.
Crossref
Crossref
Andrew A Somogyi, Stefan T Musolino & Daniel T Barratt. (2022) New pharmacological perspectives and therapeutic options for opioids: Differences matter. Anaesthesia and Intensive Care 50:1-2, pages 127-140.
Crossref
Crossref
Ee Von Moo, Kasper Harpsøe, Alexander S. Hauser, Ikuo Masuho, Hans Bräuner-Osborne, David E. Gloriam & Kirill A. Martemyanov. (2022) Ligand-directed bias of G protein signaling at the dopamine D2 receptor. Cell Chemical Biology 29:2, pages 226-238.e4.
Crossref
Crossref
Basavana Goudra. (2022)
Oliceridine- Opioid of the 21
st
Century
. Saudi Journal of Anaesthesia 16:1, pages 69.
Crossref
Crossref
A Tejus, Sharmila Sinha, Prafull Mohan & AG Mathur. (2022) Journey of oliceridine: A novel opioid. Journal of Marine Medical Society 0:0, pages 0.
Crossref
Crossref
Kaushik Sarkar, Biswajit Debsarma & Rajesh Kumar Das. (2022) 2D QSAR of 3-(Piperidin-1-yl)-5,6,7,8-Tetrahydropyrido[3,4-b] Pyrazine Derivatives With GPCR-6 Inhibitory Activity. International Journal of Quantitative Structure-Property Relationships 7:1, pages 1-27.
Crossref
Crossref
Yifei Yang, Yonghai Wang, Aixia Zuo, Chunmei Li, Wenyan Wang, Wanglin Jiang, Xiaochen Zhang, Xin Che, Yang Zhang, Wentao Wu, Xiaobo Cen, Hongbo Wang & Jingwei Tian. (2022) Synthesis, biological, and structural explorations of a series of μ-opioid receptor (MOR) agonists with high G protein signaling bias. European Journal of Medicinal Chemistry 228, pages 113986.
Crossref
Crossref
. 2022. Arzneimitteltherapie in der Palliativmedizin. Arzneimitteltherapie in der Palliativmedizin
511
774
.
Agnes Acevedo-Canabal, Fani Pantouli, Akshaya Ravichandran, Laura Rullo & Laura M. Bohn. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology
478
493
.
Kimberly A. Ramos, Ian E. James, Franck Skobieranda, David G. Soergel, Dennis Ruff & Michael J. Fossler. (2021) Two‐Part Phase 1 Multiple‐Ascending‐Dose Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of TRV734 in Healthy Adults. Clinical Pharmacology in Drug Development 11:1, pages 51-62.
Crossref
Crossref
Janna E. Finlay & Kate Leslie. (2021) Sedation/analgesia techniques for nonoperating room anesthesia: new drugs and devices. Current Opinion in Anaesthesiology 34:6, pages 678-682.
Crossref
Crossref
Yang Liu, Qiang Hu & Junyi Yang. (2021) Oliceridine for the Management of Acute Postoperative Pain. Annals of Pharmacotherapy 55:10, pages 1283-1289.
Crossref
Crossref
Florence Noble & Nicolas Marie. (2021) Biased Opioid Ligands: Revolution or Evolution?. Frontiers in Pain Research 2.
Crossref
Crossref
Jolien De Neve, Thomas M. A. Barlow, Dirk Tourwé, Frédéric Bihel, Frédéric Simonin & Steven Ballet. (2021) Comprehensive overview of biased pharmacology at the opioid receptors: biased ligands and bias factors. RSC Medicinal Chemistry 12:6, pages 828-870.
Crossref
Crossref
Rosmara Infantino, Consalvo Mattia, Pamela Locarini, Antonio Luigi Pastore, Sabatino Maione & Livio Luongo. (2021) Buprenorphine: Far Beyond the “Ceiling”. Biomolecules 11:6, pages 816.
Crossref
Crossref
Sarada S Eleswarpu & Ashraf S Habib. (2021) Oliceridine in the treatment of moderate to severe acute pain. Pain Management 11:3, pages 237-248.
Crossref
Crossref
Siyan Liao, Kai Tan, Cecilia Floyd, Daegun Bong, Michael James PinoJrJr & Chun Wu. (2021) Probing biased activation of mu-opioid receptor by the biased agonist PZM21 using all atom molecular dynamics simulation. Life Sciences 269, pages 119026.
Crossref
Crossref
Brittany M. Craft & Danial E. Baker. (2021) Oliceridine. Hospital Pharmacy, pages 001857872098713.
Crossref
Crossref
E. Andrew Townsend, S. Stevens Negus & Matthew L. Banks. (2021) Medications Development for Treatment of Opioid Use Disorder. Cold Spring Harbor Perspectives in Medicine 11:1, pages a039263.
Crossref
Crossref
Ravinder Reddy Gaddam & Ajit Vikram. 2021. Drug Discovery and Development. Drug Discovery and Development
125
136
.
Kanako Miyano, Sei Manabe, Akane Komatsu, Yuriko Fujii, Yusuke Mizobuchi, Eiko Uezono, Kaori Ohshima, Miki Nonaka, Yui Kuroda, Minoru Narita & Yasuhito Uezono. (2020) The G Protein Signal-Biased Compound TRV130; Structures, Its Site of Action and Clinical Studies. Current Topics in Medicinal Chemistry 20:31, pages 2822-2829.
Crossref
Crossref
Huw Garland & Alain Vuylsteke. (2020) Biased Agonism: The Future (and Present) of Inotropic Support. Journal of Cardiothoracic and Vascular Anesthesia 34:12, pages 3449-3451.
Crossref
Crossref
Anthony Markham. (2020) Oliceridine: First Approval. Drugs 80:16, pages 1739-1744.
Crossref
Crossref
Sergio Bergese, Richard Berkowitz, Paul Rider, Martin Ladouceur, Suzanne Griffith, Alvaro Segura Vasi, Kristina Cochrane, Linda Wase, Mark A. Demitrack & Ashraf S. Habib. (2020) Low Incidence of Postoperative Respiratory Depression with Oliceridine Compared to Morphine: A Retrospective Chart Analysis. Pain Research and Management 2020, pages 1-10.
Crossref
Crossref
Basavana Goudra, Gowri Gouda & Preet Mohinder. (2020) Recent Developments in Drugs for GI Endoscopy Sedation. Digestive Diseases and Sciences 65:10, pages 2781-2788.
Crossref
Crossref
Jane C. Ballantyne & Charles Chavkin. (2020) Will biased ligands be the opioids of the future?. Pain 161:9, pages 1945-1948.
Crossref
Crossref
Harold Minkowitz, Hernan Salazar, David Leiman, Daneshvari Solanki, Lucy Lu, Scott Reines, Michael Ryan, Mark Harnett & Neil Singla. (2020) Intravenous Tramadol is Effective in the Management of Postoperative Pain Following Abdominoplasty: A Three-Arm Randomized Placebo- and Active-Controlled Trial. Drugs in R&D 20:3, pages 225-236.
Crossref
Crossref
Joaquim Azevedo Neto, Anna Costanzini, Roberto De Giorgio, David G. Lambert, Chiara Ruzza & Girolamo Calò. (2020) Biased versus Partial Agonism in the Search for Safer Opioid Analgesics. Molecules 25:17, pages 3870.
Crossref
Crossref
Sabry Ayad, Mark A. Demitrack, David A. Burt, Cathy Michalsky, Linda Wase, Michael J. Fossler & Ashish K. Khanna. (2020) Evaluating the Incidence of Opioid-Induced Respiratory Depression Associated with Oliceridine and Morphine as Measured by the Frequency and Average Cumulative Duration of Dosing Interruption in Patients Treated for Acute Postoperative Pain. Clinical Drug Investigation 40:8, pages 755-764.
Crossref
Crossref
Amirhossein Mafi, Soo-Kyung Kim & William A. GoddardIIIIII. (2020) Mechanism of β-arrestin recruitment by the μ-opioid G protein-coupled receptor. Proceedings of the National Academy of Sciences 117:28, pages 16346-16355.
Crossref
Crossref
Anne N. Nafziger, Kelly A. Arscott, Kristina Cochrane, Franck Skobieranda, David A. Burt & Michael J. Fossler. (2019) The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Oliceridine. Clinical Pharmacology in Drug Development 9:5, pages 639-650.
Crossref
Crossref
Xiao Zhang, Shaurita D. Hutchins, Bruce E. Blough & Eric J. Vallender. (2020) In Vitro Effects of Ligand Bias on Primate Mu Opioid Receptor Downstream Signaling. International Journal of Molecular Sciences 21:11, pages 3999.
Crossref
Crossref
Jérôme Busserolles, Stéphane Lolignier, Nicolas Kerckhove, Célian Bertin, Nicolas Authier & Alain Eschalier. (2020) Replacement of current opioid drugs focusing on MOR-related strategies. Pharmacology & Therapeutics 210, pages 107519.
Crossref
Crossref
Lynn Webster & William K Schmidt. (2020) Dilemma of Addiction and Respiratory Depression in the Treatment of Pain: A Prototypical Endomorphin as a New Approach. Pain Medicine 21:5, pages 992-1004.
Crossref
Crossref
Morten Adler Hedegaard & Birgitte Holst. (2020) The Complex Signaling Pathways of the Ghrelin Receptor. Endocrinology 161:4.
Crossref
Crossref
Anna M. Gutridge, Meridith T. Robins, Robert J. Cassell, Rajendra Uprety, Kendall L. Mores, Mee Jung Ko, Gavril W. Pasternak, Susruta Majumdar & Richard M. van Rijn. (2020) G protein‐biased kratom‐alkaloids and synthetic carfentanil‐amide opioids as potential treatments for alcohol use disorder. British Journal of Pharmacology 177:7, pages 1497-1513.
Crossref
Crossref
Mie Fabricius Pedersen, Tomasz Marcin Wróbel, Emil Märcher-Rørsted, Daniel Sejer Pedersen, Thor Christian Møller, Federica Gabriele, Henrik Pedersen, Dariusz Matosiuk, Simon Richard Foster, Michel Bouvier & Hans Bräuner-Osborne. (2020) Biased agonism of clinically approved μ-opioid receptor agonists and TRV130 is not controlled by binding and signaling kinetics. Neuropharmacology 166, pages 107718.
Crossref
Crossref
Alexander Gillis, Arisbel B. Gondin, Andrea Kliewer, Julie Sanchez, Herman D. LimClaudia Alamein, Preeti Manandhar, Marina Santiago, Sebastian FritzwankerFrank SchmiedelTimothy A. Katte, Tristan Reekie, Natasha L. Grimsey, Michael Kassiou, Barrie Kellam, Cornelius Krasel, Michelle L. Halls, Mark Connor, J. Robert Lane, Stefan Schulz, Macdonald J. Christie & Meritxell Canals. (2020) Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists. Science Signaling 13:625.
Crossref
Crossref
Amirhossein Mafi, Soo-Kyung Kim & William A. GoddardIIIIII. (2020) The atomistic level structure for the activated human κ-opioid receptor bound to the full Gi protein and the MP1104 agonist. Proceedings of the National Academy of Sciences 117:11, pages 5836-5843.
Crossref
Crossref
Andrea Bedini, Lorenzo Di Cesare Mannelli, Laura Micheli, Monica Baiula, Gabriela Vaca, Rossella De Marco, Luca Gentilucci, Carla Ghelardini & Santi Spampinato. (2020) Functional Selectivity and Antinociceptive Effects of a Novel KOPr Agonist. Frontiers in Pharmacology 11.
Crossref
Crossref
Thanh K. Tran & Toan T. Nguyen. (2020) Computational study of µ-opioid receptor embedded in a realistic membrane. Journal of Physics: Conference Series 1506:1, pages 012023.
Crossref
Crossref
Huoming Huang, Wenli Wang, Xuejun Xu, Chen Zhu, Yujun Wang, Jinggen Liu, Wei Li & Wei Fu. (2020) Discovery of 3-((dimethylamino)methyl)-4-hydroxy-4-(3-methoxyphenyl)-N-phenylpiperidine-1-carboxamide as novel potent analgesic. European Journal of Medicinal Chemistry 189, pages 112070.
Crossref
Crossref
Richard J. Bodnar. (2020) Endogenous opiates and behavior: 2017. Peptides 124, pages 170223.
Crossref
Crossref
Ian E. James, Franck Skobieranda, David G. Soergel, Kimberly A. Ramos, Dennis Ruff & Michael J. Fossler. (2019) A First‐in‐Human Clinical Study With TRV734, an Orally Bioavailable G‐Protein–Biased Ligand at the μ‐Opioid Receptor. Clinical Pharmacology in Drug Development 9:2, pages 256-266.
Crossref
Crossref
Anthony T. Machi. 2020. Pain Management for Clinicians. Pain Management for Clinicians
31
72
.
Michael Camilleri. (2019) What’s in the pipeline for lower functional gastrointestinal disorders in the next 5 years?. American Journal of Physiology-Gastrointestinal and Liver Physiology 317:5, pages G640-G650.
Crossref
Crossref
Zoltan Dekan, Setareh SianatiArsalan YousufKaty J. SutcliffeAlexander GillisChristophe Mallet, Paramjit SinghAihua H. JinAnna M. WangSarasa A. MohammadiMichael StewartRanjala RatnayakeFrank FontaineErnest LaceyAndrew M. Piggott, Yan P. DuMeritxell Canals, Richard B. Sessions, Eamonn KellyRobert J. CaponPaul F. AlewoodMacDonald J. Christie. (2019) A tetrapeptide class of biased analgesics from an Australian fungus targets the µ-opioid receptor. Proceedings of the National Academy of Sciences 116:44, pages 22353-22358.
Crossref
Crossref
M. J. Kreek, B. ReedE. R. Butelman. (2019) Current status of opioid addiction treatment and related preclinical research. Science Advances 5:10.
Crossref
Crossref
John A. Zebala, Shawn L. Searle, Lynn R. Webster, Matt S. Johnson, Aaron D. Schuler, Dean Y. Maeda & Stuart J. Kahn. (2019) Desmetramadol Has the Safety and Analgesic Profile of Tramadol Without Its Metabolic Liabilities: Consecutive Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Trials. The Journal of Pain 20:10, pages 1218-1235.
Crossref
Crossref
Besma Benredjem, Jonathan Gallion, Dennis Pelletier, Paul Dallaire, Johanie Charbonneau, Darren Cawkill, Karim Nagi, Mark Gosink, Viktoryia Lukasheva, Stephen Jenkinson, Yong Ren, Christopher Somps, Brigitte Murat, Emma Van Der Westhuizen, Christian Le Gouill, Olivier Lichtarge, Anne Schmidt, Michel Bouvier & Graciela Pineyro. (2019) Exploring use of unsupervised clustering to associate signaling profiles of GPCR ligands to clinical response. Nature Communications 10:1.
Crossref
Crossref
Neil K. SinglaFranck SkobierandaDavid G. SoergelMonica SalameaDavid A. BurtMark A. DemitrackEugene R. Viscusi. (2019)
APOLLO‐2: A Randomized, Placebo and Active‐Controlled Phase
III
Study Investigating Oliceridine (
TRV
130), a G Protein–Biased Ligand at the μ‐Opioid Receptor, for Management of Moderate to Severe Acute Pain Following Abdominoplasty
. Pain Practice 19:7, pages 715-731.
Crossref
Crossref
Amelia D. Dunn, Brian Reed, Jose Erazo, Ariel Ben-Ezra & Mary Jeanne Kreek. (2019) Signaling Properties of Structurally Diverse Kappa Opioid Receptor Ligands: Toward in Vitro Models of in Vivo Responses. ACS Chemical Neuroscience 10:8, pages 3590-3600.
Crossref
Crossref
Mohammad Seyedabadi, Mohammad Hossein Ghahremani & Paul R. Albert. (2019) Biased signaling of G protein coupled receptors (GPCRs): Molecular determinants of GPCR/transducer selectivity and therapeutic potential. Pharmacology & Therapeutics 200, pages 148-178.
Crossref
Crossref
Yevgen Yudin & Tibor Rohacs. (2019) The G‐protein‐biased agents PZM21 and TRV130 are partial agonists of μ‐opioid receptor‐mediated signalling to ion channels. British Journal of Pharmacology.
Crossref
Crossref
Marco Sisignano, Michael J. Parnham & Gerd Geisslinger. (2019) Novel Approaches to Persistent Pain Therapy. Trends in Pharmacological Sciences 40:6, pages 367-377.
Crossref
Crossref
Pablo Berríos‐Cárcamo, Mario Rivera‐Meza, Mario Herrera‐Marschitz & Gerald Zapata‐Torres. (2019)
Molecular modeling of salsolinol, a full G
i
protein agonist of the μ‐opioid receptor, within the receptor binding site
. Chemical Biology & Drug Design.
Crossref
Crossref
Kathryn L. Schwienteck, Kaycee E. Faunce, Kenner C. Rice, Samuel Obeng, Yan Zhang, Bruce E. Blough, Travis W. Grim, S. Stevens Negus & Matthew L. Banks. (2019) Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats. Neuropharmacology 150, pages 200-209.
Crossref
Crossref
Marta Filizola. (2019) Insights from molecular dynamics simulations to exploit new trends for the development of improved opioid drugs. Neuroscience Letters 700, pages 50-55.
Crossref
Crossref
Kendall L. Mores, Benjamin R. Cummins, Robert J. Cassell & Richard M. van Rijn. (2019) A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists. Frontiers in Pharmacology 10.
Crossref
Crossref
Mikkel Søes Ibsen, David B. Finlay, Monica Patel, Jonathan A. Javitch, Michelle Glass & Natasha Lillia Grimsey. (2019) Cannabinoid CB1 and CB2 Receptor-Mediated Arrestin Translocation: Species, Subtype, and Agonist-Dependence. Frontiers in Pharmacology 10.
Crossref
Crossref
Aliza T. Ehrlich, Meriem Semache, Florence Gross, Dillon F. Da Fonte, Leonie Runtz, Christine Colley, Amina Mezni, Christian Le Gouill, Viktoriya Lukasheva, Mireille Hogue, Emmanuel Darcq, Michel Bouvier & Brigitte L. Kieffer. (2019) Biased Signaling of the Mu Opioid Receptor Revealed in Native Neurons. iScience 14, pages 47-57.
Crossref
Crossref
Anika Mann, Lionel Moulédous, Carine FromentPatrick R. O’Neill, Pooja Dasgupta, Thomas Günther, Gloria Brunori, Brigitte L. KiefferLawrence Toll, Michael R. BruchasNurulain T. Zaveri & Stefan Schulz. (2019) Agonist-selective NOP receptor phosphorylation correlates in vitro and in vivo and reveals differential post-activation signaling by chemically diverse agonists. Science Signaling 12:574.
Crossref
Crossref
Richard A. Bond, Emilio Y. Lucero Garcia-Rojas, Akhil Hegde & Julia K. L. Walker. (2019) Therapeutic Potential of Targeting ß-Arrestin. Frontiers in Pharmacology 10.
Crossref
Crossref
Giuseppe Deganutti, Stefano Moro & Christopher A Reynolds. (2019) Peeking at G-protein-coupled receptors through the molecular dynamics keyhole. Future Medicinal Chemistry 11:6, pages 599-615.
Crossref
Crossref
Margaret E. Olson, Lisa M. Eubanks & Kim D. Janda. (2018) Chemical Interventions for the Opioid Crisis: Key Advances and Remaining Challenges. Journal of the American Chemical Society 141:5, pages 1798-1806.
Crossref
Crossref
Yajuan Qin, Luofan Ni, Jiawei Shi, Zhiying Zhu, Saijian Shi, Ai-leen Lam, Julia Magiera, Sunderajhan Sekar, Andy Kuo, Maree T. Smith & Tingyou Li. (2018) Synthesis and Biological Evaluation of Fentanyl Analogues Modified at Phenyl Groups with Alkyls. ACS Chemical Neuroscience 10:1, pages 201-208.
Crossref
Crossref
Eugene R Viscusi. (2019) Improving the therapeutic window of conventional opioids: novel differential signaling modulators. Regional Anesthesia & Pain Medicine 44:1, pages 32-37.
Crossref
Crossref
Gavril W. Pasternak, Steven R. Childers & Ying-Xian Pan. 2020. Substance Use Disorders. Substance Use Disorders
89
125
.
Andrew Iskander & Tong J. Gan. (2018) Novel analgesics in ambulatory surgical patients. Current Opinion in Anaesthesiology 31:6, pages 685-692.
Crossref
Crossref
Dionéia Araldi, Luiz F. Ferrari & Jon D. Levine. (2018) Mu-opioid Receptor (MOR) Biased Agonists Induce Biphasic Dose-dependent Hyperalgesia and Analgesia, and Hyperalgesic Priming in the Rat. Neuroscience 394, pages 60-71.
Crossref
Crossref
Halina Machelska & Melih Ö. Celik. (2018) Advances in Achieving Opioid Analgesia Without Side Effects. Frontiers in Pharmacology 9.
Crossref
Crossref
Adrian P. Campbell & Alan V. Smrcka. (2018) Targeting G protein-coupled receptor signalling by blocking G proteins. Nature Reviews Drug Discovery 17:11, pages 789-803.
Crossref
Crossref
C. Austin Zamarripa, Shelley R. Edwards, Hina N. Qureshi, John N. Yi, Bruce E. Blough & Kevin B. Freeman. (2018) The G-protein biased mu-opioid agonist, TRV130, produces reinforcing and antinociceptive effects that are comparable to oxycodone in rats. Drug and Alcohol Dependence 192, pages 158-162.
Crossref
Crossref
Franziska Mende, Cecilie HundahlBianca Plouffe, Louise Julie Skov, Bjørn SivertsenAndreas Nygaard MadsenMichael LückmannThi Ai DiepStefan Offermanns, Thomas Michael FrimurerMichel Bouvier & Birgitte Holst. (2018) Translating biased signaling in the ghrelin receptor system into differential in vivo functions. Proceedings of the National Academy of Sciences 115:43.
Crossref
Crossref
Jyoti Madhusoodanan. (2018) Safer opioids may be on the horizon, but mitigating addiction is a long shot. Proceedings of the National Academy of Sciences 115:33, pages 8229-8231.
Crossref
Crossref
Neil SinglaMatthew BindewaldSonia SinglaDavid LeimanHarold MinkowitzStewart W. McCallumRandall J. MackRosemary KellerAlex FreyerWei Du. (2018) Efficacy and Safety of Intravenous Meloxicam in Subjects with Moderate-to-severe Pain Following Abdominoplasty. Plastic and Reconstructive Surgery - Global Open 6:6, pages e1846.
Crossref
Crossref
A. P. DAVENPORT, R. E. KUC, C. SOUTHAN & J. J. MAGUIRE. (2018) New Drugs and Emerging Therapeutic Targets in the Endothelin Signaling Pathway and Prospects for Personalized Precision Medicine. Physiological Research, pages S37-S54.
Crossref
Crossref
Martin C. Michel & Steven J. Charlton. (2018) Biased Agonism in Drug Discovery—Is It Too Soon to Choose a Path?. Molecular Pharmacology 93:4, pages 259-265.
Crossref
Crossref
Alan David Kaye, Elyse M. Cornett, Brendon Hart, Shilpadevi Patil, Andrew Pham, Matthew Spalitta & Kenneth F. Mancuso. (2018) Novel Pharmacological Nonopioid Therapies in Chronic Pain. Current Pain and Headache Reports 22:4.
Crossref
Crossref
Mohammad Zafar Imam, Andy Kuo, Sussan Ghassabian & Maree T. Smith. (2018) Progress in understanding mechanisms of opioid-induced gastrointestinal adverse effects and respiratory depression. Neuropharmacology 131, pages 238-255.
Crossref
Crossref
Joseph V. Pergolizzi, Michael H. Ossipov, Robert Taylor & Robert B. Raffa. (2018) “New-Look” Opioids: Biased Ligands. Pharmacology & Pharmacy 09:07, pages 242-249.
Crossref
Crossref
Xin Li, Wei He, Yang Chen, Guimei Yang, Hong Wan, Lei Zhang, Qiyue Hu, Jun Feng, Zhigao Zhang, Feng He, Chang Bai, Lianshan Zhang, Li You & Weikang Tao. (2017) Discovery of SHR9352: A Highly Potent G Protein-Biased μ-Opioid Receptor Agonist. ACS Omega 2:12, pages 9261-9267.
Crossref
Crossref